The Use of Polymer Chitosan in Intravesical Treatment of Urinary Bladder Cancer and Infections
AbstractThe most frequent diseases of the urinary bladder are bacterial infections and bladder cancers. For both diseases, very high recurrence rates are characteristic: 50–80% for bladder cancer and more than 50% for bladder infections, causing loss of millions of dollars per year for medical treatment and sick leave. Despite years of searching for better treatment, the prevalence of bladder infections and bladder cancer remains unchanged and is even increasing in recent years. Very encouraging results in treatment of both diseases recently culminated from studies combining biopolymer chitosan with immunotherapy, and chitosan with antibiotics for treatment of bladder cancer and cystitis, respectably. In both pathways of research, the discoveries involving chitosan reached a successful long-lasting cure. The property of chitosan that boosted the effectivity of illness-specific drugs is its ability to enhance the accessibility of these drugs to the very sources of both pathologies that individual treatments without chitosan failed to achieve. Chitosan can thus be recognised as a very promising co-player in treatment of bladder cancer and bacterial cystitis. View Full-Text
Share & Cite This Article
Erman, A.; Veranič, P. The Use of Polymer Chitosan in Intravesical Treatment of Urinary Bladder Cancer and Infections. Polymers 2018, 10, 265.
Erman A, Veranič P. The Use of Polymer Chitosan in Intravesical Treatment of Urinary Bladder Cancer and Infections. Polymers. 2018; 10(3):265.Chicago/Turabian Style
Erman, Andreja; Veranič, Peter. 2018. "The Use of Polymer Chitosan in Intravesical Treatment of Urinary Bladder Cancer and Infections." Polymers 10, no. 3: 265.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.